循环miRNA作为肺癌诊断和预后无创标志物的研究进展

摘要
图/表
参考文献(29)
相关文章 (15)

全文: PDF (482 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肺癌是全世界范围内发病率和死亡率最高的恶性肿瘤之一，严重影响人类健康。尽管用于肺癌诊断和靶向治疗的技术取得了进步，但由于缺乏精确有效的早期检测方法，目前肺癌的诊断和预后仍然不理想，生存率较低。肺癌由多种机制参与调控，其中microRNAs（miRNAs）参与转录后进行基因表达调控并伴随着肿瘤整个发生发展的过程，近期研究发现在血清和血浆的生物体液中检测到的循环miRNA表达异常与肺癌的早期诊断及预后密切相关。本文对循环miRNA进入循环系统的途径、稳定性及其作为肺癌患者早期诊断和预后的潜在生物标志物进行了综述和讨论。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杜歆玥1
	2 杨慧龄1
	2

关键词 ：循环miRNA, 非编码小分子miRNA, 肺癌, 诊断, 预后

Abstract：Lung cancer is one of the malignant tumor with the highest incidence rate and mortality rate in the world, which seriously affects human health. Despite advances in technology for lung cancer diagnosis and targeted therapy,due to the lack of accurate and effective early detection methods, the current diagnosis and prognosis of lung cancer is still not ideal, with a low survival rate. Lung cancer is regulated by a variety of mechanisms, among which microRNAs (miRNAs) participate in gene expression regulation after transcription and accompany the whole process of tumor development. Recent studies have found that abnormal expression of circulating miRNA detected in serum and plasma biological fluids is closely related to early diagnosis and prognosis of lung cancer. In this paper, the pathway, stability and potential biomarker of early diagnosis and prognosis of lung cancer are reviewed and discussed.

Key words： Circulating miRNA microRNA Lung cancer Diagnosis Prognosis

基金资助:国家自然科学基金资助项目（81272334）。

通讯作者: 杨慧龄（1971.3-），女，博士，教授；研究方向：肿瘤药理学。

作者简介: 杜歆玥（1995.12-），女，广东医科大学药学院2017级肿瘤药理学专业在读硕士研究生；研究方向：肿瘤药理学。

引用本文:

杜歆玥1,2 杨慧龄1,2. 循环miRNA作为肺癌诊断和预后无创标志物的研究进展[J]. 中国医药导报, 2020, 17(14): 31-34.
DU Xinyue1,2 YANG Huiling1,2. Research progress of circulating miRNA as a noninvasive marker for diagnosis and prognosis of lung cancer. 中国医药导报, 2020, 17(14): 31-34.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I14/31

[1] Ferlay J，Colombet M，Soerjomataram I，et al. Estimating the global cancer incidence and mortality in 2018：GLOBOCAN sources and methods [J]. Int J Cancer，2019，144（8）：1941-1953.
[2] Siegel RL，Miller KD，Jemal A. Cancer statistics，2018 [J]. CA Cancer J Clin，2018，68（1）：7-30.
[3] Wu KL，Tsai YM，Lien CT，et al. The Roles of MicroRNA in Lung Cancer [J]. Int J Mol Sci，2019，20（7）：1611.
[4] Ma X，Liang AL，Liu YJ. Research progress on the relationship between lung cancer drug-resistance and microRNAs [J]. J Cancer，2019，10（27）：6865-6875.
[5] Li G，Fang J，Wang Y，et al. MiRNA-based Therapeutic Strategy in Lung Cancer [J]. Curr Pharm Des，2018，23（39）：6011-6018.
[6] Gyoba J，Shan S，Roa W，et al. Diagnosing Lung Cancers through Examination of Micro-RNA Biomarkers in Blood，Plasma，Serum and Sputum：A Review and Summary of Current Literature [J]. Int J Mol Sci，2016，17（4）：494.
[7] Switlik WZ，Szemraj J. Circulating miRNAs as non-invasive biomarkers for non-small cell lung cancer diagnosis，prognosis and prediction of treatment response [J]. Postepy Hig Med Dosw （Online），2017，71：649-662.
[8] Zhao K，Cheng J，Chen B，et al. Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer [J]. J Thorac Dis，2017，9（10）：3735-3746.
[9] Zhang J，Li S，Li L，et al. Exosome and exosomal microRNA：trafficking，sorting，and function [J]. Genomics Proteomics Bioinformatics，2015，13（1）：17-24.
[10] Zeuschner P，Linxweiler J，Junker K. Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies [J]. Expert Rev Mol Diagn，2020，20（2）：151-167.
[11] Fuji T，Umeda Y，Nyuya A，et al. Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy [J]. Int J Cancer，2019，144（9）：2169-2180.
[12] Florijn BW，Duijs J，Levels JH，et al. Diabetic Nephropathy Alters the Distribution of Circulating Angiogenic MicroRNAs Among Extracellular Vesicles，HDL，and Ago-2 [J]. Diabetes，2019，68（12）：2287-2300.
[13] Travis WD，Brambilla E，Geisinger KR. Histological grading in lung cancer：one system for all or separate systems for each histological type? [J]. Eur Respir J，2016，47（3）：720-723.
[14] Arab A，Karimipoor M，Irani S，et al. Potential circulating miRNA signature for early detection of NSCLC [J]. Cancer Genet，2017，216-217：150-158.
[15] Song Y，Yu X，Zang Z，et al. Circulating or tissue microRNAs and extracellular vesicles as potential lung cancer biomarkers：a systematic review [J]. Int J Biol Markers，2018，33（1）：3-9.
[16] Yang Y，Hu Z，Zhou Y，et al. The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers [J]. Oncotarget，2017，8（52）：90197-90214.
[17] Geng Q，Fan T，Zhang B，et al. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer [J]. Respir Res，2014，25（15）：149-157.
[18] Nakamura H，Nishimura T. History，molecular features，and clinical importance of conventional serum biomarkers in lung cancer [J]. Surg Today，2017，47（9）：1037-1059.
[19] Zhou GH，Yang WH，Sun B. Clinical impact of serum miR-661 in diagnosis and prognosis of non-small cell lung cancer [J]. Eur Rev Med Pharmacol Sci，2017，21（24）：5696-5701.
[20] Wang SY，Li Y，J iang YS，et al. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer [J]. Eur Rev Med Pharmacol Sci，2017，21（18）：4092-4097.
[21] Tian F，Shen Y，Chen Z，et al. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer [J]. Gene，2016，591（2）：338-343.
[22] Shi GL，Chen Y，Sun Y，et al. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer [J]. Clin Lab，2017，63（1）：133-140.
[23] Sun Y，Mei H，Xu C，et al. Circulating microRNA-339-5p and -21 in plasma as an early detection predictors of lung adenocarcinoma [J]. Pathol Res Pract，2018，214（1）：119-125.
[24] Sromek M，Glogowski M，Chechlinska M，et al. Changes in plasma miR-9，miR-16，miR-205 and miR-486 levels after non-small cell lung cancer resection [J]. Cell Oncol （Dordr），2017，40（5）：529-536.
[25] Halvorsen AR，Bjaan?覸s M，LeBlanc M，et al. A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer [J]. Oncotarget，2016，7（24）：37250-37259.
[26] Tang D，Shen Y，Wang M，et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer [J]. Eur J Cancer Prev，2013，22（6）：540-548.
[27] Su K，Zhang T，Wang Y，et al. Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer [J]. World J Surg Oncol，2016，14（1）：224-229.
[28] Xu X，Zhu S，Tao Z，et al. High circulating miR-18a，miR-20a，and miR-92a expression correlates with poor prognosis in patients with non-small cell lung cancer [J]. Cancer Med，2018，7（1）：21-31.
[29] Sun B，Liu HF，Ding Y，et al. Evaluating the diagnostic and prognostic value of serum miR-770 in non-small cell lung cancer [J]. Eur Rev Med Pharmacol Sci，2018， 22（10）：3061-3066.